Comparative evaluation of Immunogenicity of monovalent type 1 Oral Poliovirus Vaccine (mOPV1) and monovalent type 3 Oral Poliovirus Vaccine (mOPV3) versus trivalent Oral Poliovirus Vaccine (tOPV): a randomised doubleblind controlled trial in South Africa

Submission date 15/11/2007	Recruitment status No longer recruiting Overall study status Completed		
Registration date 15/11/2007			
Last Edited 21/02/2012	Condition category Infections and Infestations		

- [X] Prospectively registered
- [] Protocol
- [_] Statistical analysis plan
- [X] Results
- [] Individual participant data

Plain English summary of protocol

Not provided at time of registration

Contact information

Type(s) Scientific

Contact name Dr Roland Sutter

Contact details

World Health Organization Avenue Appia 20 Geneva-27 Switzerland CH-1211 +41 (0)22 791 4682 sutterr@who.int

Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number

Secondary identifying numbers RPC236

Study information

Scientific Title

Study objectives

The study aims to demonstrate the superiority of one dose of monovalent type 1 Oral Poliovirus Vaccine (mOPV1) or monovalent type 3 Oral Poliovirus Vaccine (mOPV3) compared to trivalent Oral Poliovirus Vaccine (tOPV) in inducing seroconversion.

Ethics approval required

Old ethics approval format

Ethics approval(s)

Ethics approval received from: 1. World Health Organization (WHO) Ethics Review Committee (ERC) on the 24th October 2007 (ref: RPC236) 2. University of Cape Town's Research Ethics Committee on the 2nd October 2007 (ref: 355 /2007)

Regulatory authority approval from the Medicines Control Council South Africa is still in progress.

Study design

Interventional randomised double blind controlled trial for 3 arms of vaccine produced by GSK but randomised and unblinded for the mOPV1 vaccine produced by Panacea Biotec Ltd.

Primary study design Interventional

Secondary study design Randomised controlled trial

Study setting(s) Not specified

Study type(s) Treatment

Participant information sheet

Health condition(s) or problem(s) studied Poliomyelitis

Interventions

Control group:

2 drops (approximately 0.1 ml) standard dose of tOPV manufactured by GlaxoSmithKline (GSK) at birth.

Intervention groups:

1. 2 drops (approximately 0.1 ml) of mOPV1 manufactured by GSK at birth

2. 2 drops (approximately 0.1 ml) of mOPV1 manufactured by Panacea at birth

3. 2 drops (approximately 0.1 ml) of mOPV3 manufactured by GSK at birth

Blood collection at birth (cord blood or blood from newborn) and at 30 days.

Principal Investigator: Professor Gregory D. Hussey Institute of Infectious Disease and Molecular Medicine University of Cape Town Anzio Road, Observatory 7925 Cape Town South Africa Tel: +27 (0)21 406 6738 Fax: +27 (0)21 406 6081 Email: Gregory.Hussey@uct.ac.za

Intervention Type

Drug

Phase

Not Specified

Drug/device/biological/vaccine name(s)

Monovalent type 1 Oral Poliovirus Vaccine (mOPV1), monovalent type 3 Oral Poliovirus Vaccine (mOPV3), trivalent Oral Poliovirus Vaccine (tOPV)

Primary outcome measure

Seroconversion 30 days after a single dose of tOPV, mOPV1, or mOPV3. Measurements on humoral immunity (specific primary endpoints) as as follows: 1. One dose of mOPV1 induces significantly higher levels of seroconversion against poliovirus type 1 than one dose of tOPV

2. One dose of mOPV3 induces significantly higher levels of seroconversion against poliovirus type 3 than one dose of tOPV

Secondary outcome measures

No secondary outcome measures

Overall study start date

15/11/2007

Completion date

15/11/2009

Eligibility

Key inclusion criteria

 Healthy infants (birth weight greater than or equal to 2.5 kg and Apgar score greater than or equal to 9 at 5 minutes) born at study sites
Residing less than or equal to 50 km from study sites
Family is not planning on travel during the study period (birth to 1 month)

Participant type(s)

Patient

Age group

Neonate

Sex

Both

Target number of participants 800

Key exclusion criteria

- 1. High risk newborns
- 2. Other newborns requiring hospitalisation
- 3. Birthweight less than 2.5 kg
- 4. Apgar score less than 9 at 5 minutes
- 5. Infants residing more than 50 km from study sites
- 6. Infants whose families are planning to be absent during one month study period
- 7. A diagnosis or suspicion of B cell immunodeficiency in participant or immediate family

The study will not collect information on acquired immunodefiency disease or Human Immunodeficiency Virus (HIV) status of mother or study subject.

Date of first enrolment

15/11/2007

Date of final enrolment 15/11/2009

Locations

Countries of recruitment South Africa

Switzerland

Study participating centre World Health Organization Geneva-27 Switzerland CH-1211

Sponsor information

Organisation

World Health Organization (WHO) (Switzerland)

Sponsor details Avenue Appia 20 Geneva-27 Switzerland CH-1211 +41 (0)22 791 4682 sutterr@who.int

Sponsor type Research organisation

Website http://www.who.int/en/

ROR https://ror.org/01f80g185

Funder(s)

Funder type Research organisation

Funder Name World Health Organization (WHO) (Switzerland)

Alternative Name(s)

, , Всемирная организация здравоохранения, Organisation mondiale de la Santé, Organización Mundial de la Salud, WHO, , BO3, OMS

Funding Body Type Private sector organisation

Funding Body Subtype International organizations

Location

Switzerland

Funder Name Gates Foundation (USA)

Funder Name International Financing Facility for Immunisations (IFFIm) (UK)

Results and Publications

Publication and dissemination plan

Not provided at time of registration

Intention to publish date

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Not provided at time of registration

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	results	15/01/2012		Yes	No